With demand for synthetic DNA on the rise among researchers worldwide, San Diego-based Molecular Assemblies is making a push to commercialize enzymatic DNA synthesis with a newly acquired $12.2 million in Series A financing.
The company’s approach allows it to produce long and accurate DNA sequences that can be used for CAR-T and gene-editing therapies, adding new traits to crops and livestock, and producing industrial chemicals, as well as making it possible to store great amounts of data in a very small area.
“Our ability to reliably, affordably, and sustainably produce long, high-quality DNA can accelerate life science research and transform the information storage industry by enabling integrated systems that can write and read DNA data,” CEO Michael J. Kamdar said in a statement.
Kamdar says this recent round of funding will allow the company to expand its 16-person team to about 25 people, and prepare a product for commercialization within the next two years.
- GenomeWeb: Molecular Assemblies Raising Cash, Awareness for Enzymatic DNA Synthesis
- The San Diego Union-Tribune: San Diego’s Molecular Assemblies raises $12.2 million
- Xconomy: Molecular Assemblies Raises $12M to Advance Enzymatic DNA Synthesis